Determining quantitative targets for public funding of tuberculosis research and development

Show simple item record Walwyn, David Richard 2013-06-05T14:01:16Z 2013-06-05T14:01:16Z 2013-03-08
dc.description.abstract South Africa’s expenditure on tuberculosis (TB) research and development (R&D) is insignificant relative to both its disease burden and the expenditure of some comparator countries with a minimal TB incidence. In 2010, the country had the second highest TB incidence rate in the world (796 per 100,000 population), and the third highest number of new TB cases (490,000 or 6% of the global total). Although it has a large TB treatment program (about $588 million per year), TB R&D funding is small both in absolute terms and relative to its total R&D expenditure. Given the risk and the high cost associated with drug discovery R&D, such neglect may make strategic sense. However in this analysis it is shown that TB R&D presents a unique opportunity to the national treasuries of all high-burden countries. Using two separate estimation methods (global justice and return on investment), it is concluded that most countries, including South Africa, are under-investing in TB R&D. Specific investment targets for a range of countries, particularly in areas of applied research, are developed. This work supports the outcome of the World Health Organization’s Consultative Expert Working Group on Research and Development: Financing and Coordination, which has called for “a process leading to the negotiation of a binding agreement on R&D relevant to the health needs of developing countries”. en
dc.description.librarian am2013 en
dc.description.librarian ai2013 en
dc.description.uri en
dc.identifier.citation Walwyn, DR 2013, 'Determining quantitative targets for public funding of tuberculosis research and development', Health Research Policy and Systems 2013, vol. 11, p. 10. en
dc.identifier.issn 1478-4505
dc.identifier.other 10.1186/1478-4505-11-10
dc.language.iso en en
dc.publisher BioMed Central en
dc.rights © 2013 Walwyn; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. en
dc.subject.lcsh Tuberculosis -- Prevention en
dc.subject.lcsh Tuberculosis -- South Africa -- Prevention en
dc.subject.lcsh Tuberculosis -- Research en
dc.subject.lcsh Tuberculosis -- Research -- South Africa en
dc.subject.lcsh Tuberculosis -- Developing countries -- Prevention en
dc.subject.lcsh Tuberculosis -- Research -- Developing countries en
dc.title Determining quantitative targets for public funding of tuberculosis research and development en
dc.type Article en

Files in this item

This item appears in the following Collection(s)

Show simple item record